KR900013951A - 안약용 방부제 - Google Patents

안약용 방부제 Download PDF

Info

Publication number
KR900013951A
KR900013951A KR1019900004039A KR900004039A KR900013951A KR 900013951 A KR900013951 A KR 900013951A KR 1019900004039 A KR1019900004039 A KR 1019900004039A KR 900004039 A KR900004039 A KR 900004039A KR 900013951 A KR900013951 A KR 900013951A
Authority
KR
South Korea
Prior art keywords
volume
weight
inflammatory
ophthalmologically acceptable
drug
Prior art date
Application number
KR1019900004039A
Other languages
English (en)
Other versions
KR0184864B1 (ko
Inventor
차이 로저 후 쳉
마릴린 리드게이트 데보라
Original Assignee
허비히 폰 모르쯔
신텍스 인크
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 허비히 폰 모르쯔, 신텍스 인크 filed Critical 허비히 폰 모르쯔
Publication of KR900013951A publication Critical patent/KR900013951A/ko
Application granted granted Critical
Publication of KR0184864B1 publication Critical patent/KR0184864B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

내용 없음

Description

안약용 방부제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (16)

  1. 안과학적으로 허용되는 비스테로이드성 항염증성 카르복실기를 함유하는 안과 치료용 약물의 유효량, 안과학적으로 허용되는 안과 치료용 항생물질의 유효량, 4급 암모늄 방부제, 비이온성 폴리옥시에틸화 옥틸페놀 표면 활성제의 안정화량 및, 수용성 부형제로 되어 있는 안과학적으로 허용되는 비스테로이드성 항염증성의약품 제제.
  2. 제1항에 있어서, 4급 암모늄 방부제가 염화 벤즈알코늄인 것을 특징으로 하는 안과학적으로 허용되는 비스테로이드성 항염증성 의약품 제제.
  3. 제1항에 있어서, 비이온성 폴리옥시에틸화 옥틸페놀 표면 활성제가 옥톡시놀 40이고 항생 물질이 토브라미신인 것을 특징으로 하는 안과학적으로 허용되는 비스테로이드성 항염증성 의약품 제제.
  4. 제1항에 있어서, 에데트산 아나트륨을 함유한 안과학적으로 허용되는 비스테로이드성 함염증성 의약품 제제.
  5. 제1항에 있어서, 안과학적으로 허용되는 비스테로이드성 항염증성 카르복실기를 함유하는 약물이 케토롤락, 인도메타신, 플루르비프로펜, 디클로페낙 및 슈프로펜으로 되어 있는 군 중에서 선택되는 것을 특징으로 하는 안과학적으로 허용되는 비스테로이드성 항염증성 의약품 제제.
  6. 제5항에 있어서, 안과학적으로 허용되는 비스테로이드성 항염증성 카르복실기를 함유하는 약물이 케토롤락트로메타민인 것을 특징으로 하는 안과학적으로 허용되는 비스테로이드성 항염증성 의약품 제제.
  7. 제1항에 있어서, NSAID 0.001% 내지 10.0%중량/부피, 항생물질 0.001% 내지 10.0중량/부피, 방부제 0.001% 내지 1.0중량/부피, 표면 활성제 0.001% 내지 1.0%중량/부피, 및 정제수 100%로 만드는데 충분한 량으로 되어 있는 것을 특징으로 하는 안과학적으로 허용되는 비스테로이드성 항염증성 의약품 제제.
  8. 제7항에 있어서, 케토롤락 트로메타민 0.001% 내지 10.0중량/부피, 토브라미신 0.001% 내지 10.0중량/부피, 방부제 0.001% 내지 1.0중량/부피, 표면 활성제 0.001% 내지 1.0중량/부피, 정제수 100%를 만드는데 충분한 량으로 되어 있는 것을 특징으로 하는 안과학적으로 허용되는 비스테로이드성 항염증성 의약품 제제.
  9. 제7항에 있어서, 방부제가 염화 벤즈알코늄이고 표면 활성제가 옥톡시놀 40인 것을 특징으로 하는 안과학적으로 허용되는 비스테로이드성 항염증성 의약품 제제.
  10. 제8항에 있어서, 킬레이트제 0.01% 내지 1.0중량/부피, 긴장화제 누액과 등장성을 어덱 하는데 충분한 량, 및 1N NaOH 또는 1N HCl pH7.4(0.4%)로 조정하는데 충분한 량을 추가하는 것으로 되어 있는 것을 특징으로 하는 안과학적으로 허용되는 비스테로이드성 항염증성 의약품 제제.
  11. 제9항에 있어서, 케토롤락 트로메타민 0.50%중량/부피, 토브라미신 0.30%중량/부피, BAC(50% 수용액)0.02중량%중량/부피, 옥톡시놀 40(70% 수용액)0.01%중량/부피, EDTA Na20.10%중량/부피, NaCl 0.18%중량/부피, 붕산 0.9%중량/부피, 붕산 나트륨 0.45%중량/부피 1N NaOH 또는 1N HCl pH7.4(0.4%)로 조정하는데 충분한 량, 및 정제수 100%로 만드는데 충분한 량으로 되어 있는 것을 특징으로 하는 안과학적으로 허용되는 비스테로이드성 항염증성 의약품 제제.
  12. 안과학적으로 허용되는 비스테로이드성 항염증성 카르복실기를 함유하는 안과 치료용 약물의 유효량, 안과 치료용 항생물질의 유효량, 4급 암모늄 방부제, 비이온성 폴리옥시에틸화 옥틸페놀 표면 활성제의 안정화량, 및 수용성 부형제로 구성된 제제를 안과 질병으로 고통받는 포유동물에 투여하는 것으로 되어 있는 안과 질병의 치료 방법.
  13. 제12항에 있어서, 방부제가 염화 벤즈알코늄이고 상기 표면 활성제가 옥톡시놀 40인 것을 특징으로 하는 안과 질병의 치료 방법.
  14. 제12항에 있어서, 안과학적으로 허용되는 비스테로이드성 항염증성 카르복실기를 함유하는 약물이 케토롤락, 인도메타신, 플루르비프로펜, 디클로페낙, 및 숙프로펜으로 되어 있는 군중에서 선택되는 것을 특징으로 하는 안과 질병의 치료 방법.
  15. 제12항에 있어서, 안과학적으로 허용되는 비스테로이드성 항염증성 카르복실기를 함유하는 약물이 케토롤락 트로메타민이고 항생물질이 토브라미신인 것을 특징으로 하는 안과 질병의 치료 방법.
  16. 제15항에 있어서, 비스테로이드성 항염증 약물 제제가 케토롤락 트로메타민 0.50%중량/부피, 토브라미신 0.30%중량/부피, BAC(50% 수용액) 0.01%중량/부피, 옥톡시놀 40(70% 수용액)0.01%중량/부피, EDTA Na20.10%중량/부피, NaCl 0.18%중량/부피, 붕산 0.9%중량/부피, 붕산 나트륨 0.45%중량/부피 1N NaOH 또는 1N HCl pH7.4(0.4%)로 조정하는데 충분한 량, 및 정제수 100%로 만드는데 충분한 량으로 되어 있는 것을 특징으로 하는 안과 질병의 치료 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900004039A 1989-03-28 1990-03-26 안약용 방부제 KR0184864B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US329451 1989-03-28
US07/329,451 US5414011A (en) 1987-09-11 1989-03-28 Preservative system for ophthalmic formulations
US329,451 1989-03-28

Publications (2)

Publication Number Publication Date
KR900013951A true KR900013951A (ko) 1990-10-22
KR0184864B1 KR0184864B1 (ko) 1999-05-01

Family

ID=23285465

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900004039A KR0184864B1 (ko) 1989-03-28 1990-03-26 안약용 방부제

Country Status (8)

Country Link
US (1) US5414011A (ko)
EP (1) EP0390071A1 (ko)
JP (1) JP2954642B2 (ko)
KR (1) KR0184864B1 (ko)
AU (1) AU631849B2 (ko)
CA (1) CA2013188C (ko)
NZ (1) NZ233101A (ko)
ZA (1) ZA902357B (ko)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2012532A6 (es) * 1988-07-15 1990-04-01 Cusi Lab Un procedimiento para la preparacion de una solucion acuosa de b-metil-4-(2' -tienilcarbonil)fenilacetato de lisina para aplicacion topica oftalmica.
IT1250691B (it) * 1991-07-22 1995-04-21 Giancarlo Santus Composizioni terapeutiche per somministrazione intranasale comprendenti ketorolac.
ES2079994B1 (es) * 1992-10-07 1996-08-01 Cusi Lab Formulacion farmaceutica a base de polimixina-trimetoprim y un agente antiinflamatorio para su utilizacion topica oftalmica y otica.
US5474985A (en) * 1993-12-22 1995-12-12 The Regents Of The University Of California Preventing and treating elevated intraocular pressure associated with administered or endogenous steroids using non-steroidal cyclooxygenase inhibitors
TW358812B (en) * 1994-03-15 1999-05-21 Senju Pharma Co Method for stabilizing pranoprofen and a composition and a package thereof
ES2079320B1 (es) * 1994-05-17 1996-10-16 Cusi Lab Disolucion oftalmica a base de un diclofenaco y tobramicina y sus aplicaciones.
AU3609795A (en) * 1994-10-10 1996-05-02 Novartis Ag Ophthalmic and aural compositions containing diclofenac potassium
JP3170619B2 (ja) * 1995-04-20 2001-05-28 参天製薬株式会社 有機アミンを配合したプラノプロフェン点眼液
US5599535A (en) * 1995-06-07 1997-02-04 Regents Of The University Of California Methods for the cyto-protection of the trabecular meshwork
US5674888A (en) * 1995-06-07 1997-10-07 University Of California Method for the treatment of a trabecular meshwork whose cells are subject to inhibition of cell division
JPH09278653A (ja) * 1996-04-05 1997-10-28 Santen Pharmaceut Co Ltd 網膜疾患治療剤
US5980928A (en) * 1997-07-29 1999-11-09 Terry; Paul B. Implant for preventing conjunctivitis in cattle
US6166012A (en) * 1999-07-30 2000-12-26 Allergan Sales, Inc. Antibiotic compositions and method for using same
US6552020B1 (en) 1999-07-30 2003-04-22 Allergan, Inc. Compositions including antibiotics and methods for using same
AU1548001A (en) 1999-11-24 2001-06-04 Wakamoto Pharmaceutical Co., Ltd. Ophthalmic aqueous preparation
US20020035107A1 (en) * 2000-06-20 2002-03-21 Stefan Henke Highly concentrated stable meloxicam solutions
DE10161077A1 (de) 2001-12-12 2003-06-18 Boehringer Ingelheim Vetmed Hochkonzentrierte stabile Meloxicamlösungen zur nadellosen Injektion
US7166641B2 (en) * 2002-10-02 2007-01-23 Yung Shin Pharmaceutical Industrial Co., Ltd. Pharmaceutically acceptable salts containing local anesthetic and anti-inflammatory activities and methods for preparing the same
US8992980B2 (en) 2002-10-25 2015-03-31 Boehringer Ingelheim Vetmedica Gmbh Water-soluble meloxicam granules
WO2004064828A1 (ja) 2003-01-21 2004-08-05 Senju Pharmaceutical Co., Ltd. ２−アミノ−３−(４−ブロモベンゾイル)フェニル酢酸含有水性液剤
US8008338B2 (en) 2003-06-03 2011-08-30 Allergan, Inc. Ketorolac tromethamine compositions for treating or preventing ocular pain
ATE444732T1 (de) 2003-08-07 2009-10-15 Allergan Inc Zusammensetzungen zur abgabe von therapeutika in die augen und verfahren zu ihrer herstellung und verwendung
PL1683526T3 (pl) * 2003-11-14 2012-09-28 Senju Pharma Co Preparat wodnego roztworu zawierający antybiotyk aminoglikozydowy i bromfenak
WO2005049014A1 (en) * 2003-11-18 2005-06-02 Pharmacia Corporation Cox-2 inhibitors for the treatment or prevention of diabetes-related ocular disorders
EP1568369A1 (en) * 2004-02-23 2005-08-31 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the treatment of respiratory diseases in pigs
ES2245611B1 (es) * 2004-06-29 2007-03-16 Laboratorio Reig Jofre, S.A. Composicion farmaceutica para uso ototopico.
CN1981869B (zh) * 2005-12-14 2011-04-06 信谊药厂 含普拉洛芬的复方非载体抗菌眼用制剂及其制备方法
ATE481087T1 (de) * 2007-07-09 2010-10-15 Novagali Pharma Sa Öl in wasser emulsionen enthaltend nsaid und quartär ammoniumhalogenide
US8512687B2 (en) 2007-07-09 2013-08-20 Novagali Pharma Sa Oil in water emulsion comprising NSAIDs and quaternary ammonium halides
CA2730221C (en) * 2007-07-09 2016-02-02 Novagali Pharma Sa Oil in water emulsion comprising nsaids and quaternary ammonium halides
JP5668476B2 (ja) * 2007-10-08 2015-02-12 オーリニア・ファーマシューティカルズ・インコーポレイテッドＡｕｒｉｎｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． カルシニューリン阻害剤またはｍＴＯＲ阻害剤を含む眼科用組成物
WO2009070530A1 (en) * 2007-11-27 2009-06-04 Alcon Research, Ltd. Topical ophthalmic or otic solution formulations containing moxifloxacin hydrochloride and dexamethasone phosphate
US7842714B2 (en) * 2008-03-03 2010-11-30 Allergan, Inc. Ketorolac tromethamine compositions for treating ocular pain
US9192571B2 (en) * 2008-03-03 2015-11-24 Allergan, Inc. Ketorolac tromethamine compositions for treating or preventing ocular pain
CN102026665A (zh) * 2008-05-19 2011-04-20 爱尔康研究有限公司 含有羧基乙烯基聚合物和聚维酮聚合物的药物组合物
US20120027716A1 (en) * 2008-06-12 2012-02-02 Foresight Biotherapeutics, Inc. Povidone Iodine, A Novel Alternative Preservative For Ophthalmic Compositions
WO2010144194A1 (en) * 2009-06-09 2010-12-16 Lux Biosciences, Inc. Topical drug delivery systems for ophthalmic use
IN2012DN03157A (ko) 2009-10-12 2015-09-18 Boehringer Ingelheim Vetmed
AU2010347598B2 (en) 2010-03-03 2014-11-27 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats
US9795568B2 (en) 2010-05-05 2017-10-24 Boehringer Ingelheim Vetmedica Gmbh Low concentration meloxicam tablets
RU2625755C2 (ru) 2011-01-18 2017-07-18 Сэндзю Фармасьютикал Ко., Лтд. Жидкая композиция с бромфенаком на водной основе, обладающая консервирующей эффективностью
JP2013082682A (ja) * 2011-09-29 2013-05-09 Senju Pharmaceut Co Ltd 亜塩素酸塩を含有する水性製剤
ES2650748T3 (es) * 2013-01-31 2018-01-22 Senju Pharmaceutical Co. Ltd Solución acuosa estable
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
WO2020113075A1 (en) * 2018-11-29 2020-06-04 Cellula Llc The composition of umbilical cord blood serum
CN115337264A (zh) * 2022-09-26 2022-11-15 福建师范大学 一种改进增效的妥布霉素滴眼液及制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4087539A (en) * 1976-07-14 1978-05-02 Syntex (U.S.A.) Inc. 5-(2-Furoyl)-, 5-(2-thenoyl)-, 5-(3-furoyl)- and 5-(3-thenoyl)-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid derivatives and process for the production thereof
US4089969A (en) * 1976-07-14 1978-05-16 Syntex (U.S.A.) Inc. 5-Aroyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid derivatives and process for the production thereof
US4087538A (en) * 1976-09-09 1978-05-02 Merck & Co., Inc. Ophthalmic suspensions
US4097579A (en) * 1977-03-31 1978-06-27 Syntex (U.S.A.) Inc. 5-(2-Pyrroyl)-1,2-dihydro-3H-pyrrolo 1,2-a!pyrrole-1-carboxylic acid derivatives and process for the production thereof
CA1118792A (en) * 1977-12-22 1982-02-23 Douglas L. Swallow Tetracyclononane derivatives
US4230724A (en) * 1979-07-16 1980-10-28 Allergan Pharmaceuticals, Inc. Method of treating vascularization of the eye with Flurbiprofen
US4232038A (en) * 1979-08-31 1980-11-04 Syntex (U.S.A.) Inc. 5-Alkylsulfinylbenzoyl- and 5-alkylsulfonylbenzoyl-1,2-dihydro-3H-pyrrolo[1,]pyrrole-1-carboxylic acids
NZ196700A (en) * 1980-04-18 1983-04-12 Smith & Nephew Ass Anti-inflammatory compositions containing 5-benzoyl-1-methylpyrrole-2-acetic acid derivatives
US4336152A (en) * 1981-07-06 1982-06-22 American Cyanamid Company Disinfectant/cleanser compositions exhibiting reduced eye irritancy potential
US4336151A (en) * 1981-07-06 1982-06-22 American Cyanamid Company Disinfectant/cleanser compositions exhibiting reduced eye irritancy potential
JPS58126810A (ja) * 1981-12-24 1983-07-28 Kaken Pharmaceut Co Ltd 抗炎症眼科用液剤およびその製法
US4559343A (en) * 1982-09-07 1985-12-17 Alcon Laboratories, Inc. Nonirritating aqueous ophthalmic compositions comfort formulation for ocular therapeutic agents
US4500538A (en) * 1983-03-14 1985-02-19 Merck & Co., Inc. Benzothiazolesulfonamide derivatives for the topical treatment of elevated intraocular pressure
US4474751A (en) * 1983-05-16 1984-10-02 Merck & Co., Inc. Ophthalmic drug delivery system utilizing thermosetting gels
JPS6023318A (ja) * 1983-07-19 1985-02-05 Lion Corp 点眼液
JPS60184013A (ja) * 1984-03-01 1985-09-19 Yoshitomi Pharmaceut Ind Ltd 点眼剤
IL87724A (en) * 1987-09-11 1992-01-15 Syntex Inc Ophthalmic compositions,their preparation and use

Also Published As

Publication number Publication date
ZA902357B (en) 1991-11-27
CA2013188A1 (en) 1990-09-28
US5414011A (en) 1995-05-09
JP2954642B2 (ja) 1999-09-27
CA2013188C (en) 2000-03-14
NZ233101A (en) 1992-10-28
AU631849B2 (en) 1992-12-10
KR0184864B1 (ko) 1999-05-01
EP0390071A1 (en) 1990-10-03
AU5220190A (en) 1990-10-11
JPH02286627A (ja) 1990-11-26

Similar Documents

Publication Publication Date Title
KR900013951A (ko) 안약용 방부제
KR890004691A (ko) 안과 제제물용 방부 시스템
ES2247711T3 (es) Composiciones oftalmicas que contienen terpenoides para lentes de contacto.
US5110493A (en) Ophthalmic NSAID formulations containing a quaternary ammonium preservative and a nonionic surfactant
Kuckelkorn et al. Emergency treatment of chemical and thermal eye burns
US5653972A (en) Preserved ophthalmic drug compositions containing polymeric quaternary ammonium compounds
Robert et al. Lack of correlation between mucus gel thickness and gastric cytoprotection in rats
RU94041223A (ru) Средство для лечения мотонейроновых заболеваний
KR910007511A (ko) 콜라겐 함유 안약 제형
AU6545301A (en) Pharmaceutical composition for ophthalmic use
DE69130529D1 (de) Behandlung von erektionversagen
EE03235B1 (et) Emulsioonvorm, selle valmistamise protsess ja kasutamine
LEMP Artificial tear solutions
CA2392050A1 (en) Pharmaceutical formulations containing zolmitriptan
AU776789B2 (en) Ophthalmic anti-allergy compositions suitable for use with contact lenses
KR920703041A (ko) 통증을 수반하는 염증성 또는 알레르기성 질환치료에 사용되는 성분물과 그 방법
DE69733089D1 (de) Behandlung der osteoarthritis durch verabreichung von poly-n-acetyl-d-glucosamin
CA2189424A1 (en) Non-steroidal anti-inflammatory ophthalmic suspensions
EP0369880A1 (fr) Nouvelles compositions pharmaceutiques agissant sur la presbytie et leur procédé d'obtention
DE69824326D1 (de) Pharmazeutische Emulsion enthaltend Sorbinsäure, Na-EDTA und Borsäure
CA2468664A1 (en) Ketorolac tromethamine compositions for treating or preventing ocular pain
PE33396A1 (es) Composicion para el tratamiento del ansia de nicotina y/o los sintomas de abstinencia de fumar
CA2166704A1 (en) Arsenic medicaments for the treatment of chronic fatigue syndrome
FR2833493B1 (fr) Forme galenique solide et soluble pour l'administration occulaire de principes actifs et procede de fabrication d'un insert ophtalmique solide et soluble
DE69535787D1 (de) Verbesserte dnase flüssige lösungen

Legal Events

Date Code Title Description
A201 Request for examination
AMND Amendment
E902 Notification of reason for refusal
E601 Decision to refuse application
J201 Request for trial against refusal decision
B701 Decision to grant
GRNT Written decision to grant
G170 Re-publication after modification of scope of protection [patent]
FPAY Annual fee payment

Payment date: 20110929

Year of fee payment: 14

FPAY Annual fee payment

Payment date: 20121129

Year of fee payment: 15

EXPY Expiration of term